Friday, 22 Jun 2018

You are here

SPAR Predicts ILD Progression in Systemic Sclerosis

The development and progression of interstitial lung disease in systemic sclerosis can be an ominous finding. A new analysis of two independent clinical trial cohorts shows that oxygen saturation (SpO2) < 94% after 6 minute walk time (6MWT) and the presence of arthritis predicted the development of ILD in SSc. (SPAR: SPO2 and ARthritis) 

A total of 215 SSc patients with mild ILD (without pulmonary HTN or COPD) were followed prospectively with SpO2 levels, high-resolution computed tomography (HRCT) and pulmonary function tests.

ILD progression was defined as a relative decrease in forced vital capacity (FVC) ≥15%, or FVC ≥10% combined with diffusing capacity for carbon monoxide (DLCO) ≥15% at 1-year.

Between 21-26% of SSc patients showed ILD progression. Independent predictors of progression included lower SpO2 after 6MWT and arthritis.

This SPAR model (SPO2 and ARthritis) increased the prediction rate from 25.5% to 91.7% with an area under the curve of 0.83 (95% CI: 0.73 to 0.93).

These simple measures might be helpful for the risk stratification of SSc patients. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Abatacept Misses in Lupus Nephritis

Dr. Richard Furie, MD, of Northwell Health in New York, presented the findings ofa large phase III trial of abatacept (Orencia) in lupus nephritis showing the agent failed to achieve a complete renal response.

Data presented at EULAR 2018 showed that at one year, a total of 35.1% of patients receiving abatacept achieved complete renal response, as did 33.5% of those randomized to placebo (P=0.73). 

The Stress - Autoimmune Disease Connection

"Can stresss be the cause of my autoimmune disease?" is an often launched question met with shrugs of uncertainty or strongly held beliefs rooted in bias moreso than fact.

Swedish investigators have analyzed a large registry cohort and shown that exposure to stress-related disorders yields a significantly increased risk of autoimmune disease. They analyzed 106,464 patients with stress-related disorders, with 126,652 full siblings, and over a million non-stressed matched controls to assess a future risk of autoimmune disease.

The Microbiome and Lupus Connection Reviewed

In the current issue of the New England Journal of Medicine, Drs. James Rosenbaum and Gregg Silverstein review the pathogenesis of systemic lupus erythematosus (SLE) from the viewpoint of a dysbiolsis.

The complexity of the trillions of organisms that constitute our microbiome underscores its multiplicity of functions, including nutrient, metabolic and immune shaping functions.

Low Disease Activity in Lupus Limits Damage

Patients with systemic lupus erythematosus (SLE) who were assessed as being in a low disease activity state during more than half of clinical visits had a decrease in organ damage events of approximately 50%, a retrospective study found.

Long Term Remission in SLE is Possible?

Researchers from the Toronto Lupus Clinic have described an atypical “monophasic” course in a small number (7.5%) of systemic lupus erythematosus (SLE) patients who achieved and sustained clinical remission, with most off of all medications for an average of 18 years.

Their inception SLE cohort includes patients enrolled within 18 mos of diagnosis.